Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial.
BACKGROUND
Neonatal herpes simplex virus (HSV) infections limited to the skin, eyes and mouth (SEM) can result in neurologic impairment. A direct correlation exists between the development of neurologic deficits and the frequency of cutaneous HSV recurrences. Thus, the National Institutes of Allergy and Infectious Diseases Collaborative Antiviral Study Group conducted a Phase I/II trial of oral acyclovir therapy for the suppression of cutaneous recurrences after SEM disease in 26 neonates.


METHODS
Infants < or = 1 month of age with virologically confirmed HSV-2 SEM disease were eligible for enrollment. Suppressive oral acyclovir therapy (300 mg/m2/dose given either twice daily or three times per day) was administered for 6 months.


RESULTS
Twelve (46%) of the 26 infants developed neutropenia (< 1000 cells/mm3) while receiving acyclovir. Thirteen (81%) of the 16 infants who received drug 3 times per day experienced no recurrences of skin lesions while receiving therapy. In comparison, a previous Collaborative Antiviral Study Group study found that only 54% of infants have no cutaneous recurrences in the 6 months after resolution of neonatal HSV disease if oral acyclovir suppressive therapy is not initiated. In one infant, HSV DNA was detected in the cerebrospinal fluid during a cutaneous recurrence, and an acyclovir-resistant HSV mutant was isolated from another patient during the course of the study.


CONCLUSIONS
Administration of oral acyclovir can prevent cutaneous recurrences of HSV after neonatal SEM disease. The effect of such therapy on neurologic outcome must be assessed in a larger, Phase III study. As such, additional investigation is necessary before routine use of suppressive therapy in this population can be recommended.
Kimberlin
D
D
Department of Pediatrics, University of Alabama at Birmingham 35233, USA.
Powell
D
D
Gruber
W
W
Diaz
P
P
Arvin
A
A
Kumar
M
M
Jacobs
R
R
Van Dyke
R
R
Burchett
S
S
Soong
S J
SJ
Lakeman
A
A
Whitley
R
R
D000212:Acyclovir / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000284:Administration, Oral; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004351:Drug Resistance; D015828:Eye Infections, Viral / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology; D005260:Female; D006558:Herpes Genitalis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology; D018258:Herpesvirus 2, Human / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009059:Mouth Diseases / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology; D012008:Recurrence; D012189:Retrospective Studies; D017193:Skin Diseases, Viral / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology
D000998:Antiviral Agents; D000212:Acyclovir